Alar Pharmaceuticals Inc

As of June 30, 2026, Alar Pharmaceuticals Inc carries a market capitalization of 7.78B, placing it among publicly traded companies globally. Its enterprise value stands at 5.50B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Alar Pharmaceuticals Inc's next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Alar Pharmaceuticals Inc has 66.80M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 2,596.01, and the price-to-book ratio stands at 3.27.

These figures are as of June 30, 2026. The EV/Sales ratio of 1,833.05 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 5.50B versus a market cap of 7.78B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Alar Pharmaceuticals Inc maintains a current ratio of 38.77, meaning it holds 38.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.08, indicating conservative leverage, while an interest coverage ratio of -1,918.90 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Alar Pharmaceuticals Inc posted a negative return on equity (ROE) of -2.99, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -2.90, reflecting losses generated across the asset base. The company generates approximately 97,560.98 in revenue per employee across its workforce of 30.75, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Alar Pharmaceuticals Inc recorded 19.62M in income tax expense. The company reported a pretax loss of -52.51M and -72.13M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Alar Pharmaceuticals Inc's stock has declined approximately 69.93% over the past 52 weeks. The 50-day moving average sits at 94.27, while the 200-day moving average is 153.76.

Over the twelve months ended June 30, 2026, Alar Pharmaceuticals Inc generated 3.00M in revenue and converted that into -72.13M in net income, yielding earnings per share of -1.08. EBITDA reached -165.02M, while operating income came in at -171.25M.

As of June 30, 2026, Alar Pharmaceuticals Inc holds 2.28B in cash and equivalents against 1.85M in total debt, resulting in a net debt position of -1.80B. Total book value stands at 2.38B, with working capital of 2.26B providing operational flexibility.

Alar Pharmaceuticals Inc produced -186.65M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -2.79M in capital expenditures, free cash flow totaled -189.44M - equivalent to -2.83 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -5,708.40 and net profit margin of -2,404.27 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Alar Pharmaceuticals Inc paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -2.43: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.26, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Alar Pharmaceuticals Inc shareholders.

As of June 30, 2026, Alar Pharmaceuticals Inc has an Altman Z-Score of 65.47, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.